Literature DB >> 9924341

MIB-1 and PC-10 immunostaining for the assessment of proliferative activity in primary acquired melanosis without and with atypia.

I Chowers1, N Livni, A Solomon, G Zajicek, J Frucht-Pery, R Folberg, J Pe'er.   

Abstract

AIMS: To compare the proliferative activity of intraepithelial melanocytes in primary acquired melanosis (PAM) without atypia and PAM with atypia by immunohistochemical staining for the Ki-67 antigen and the proliferating cell nuclear antigen (PCNA).
METHODS: Formalin fixed, paraffin embedded sections from 35 archival specimens of PAM without atypia (n = 19) and with atypia (n = 16) were studied by immunostaining with MIB-1 and PC-10 monoclonal antibodies that react with the Ki-67 antigen and PCNA respectively. The results were calculated as the mean number of positive cells per eyepiece grid. All specimens were evaluated by two masked observers, and the interobserver reproducibility was assessed.
RESULTS: The means of the positive cell count in PAM with atypia were significantly higher compared with PAM without atypia for both observers, in both the PC-10 and the MIB-1 stained sections. In a linear least square model that estimated the interobserver and between group variation, the difference of MIB-1 and PC-10 positive cell count between PAM without and with atypia remained highly significant. The difference between the observers was not significant.
CONCLUSIONS: Immunostaining with MIB-1 and PC-10 demonstrated that PAM with atypia has higher proliferative activity than PAM without atypia. This method was found to be reproducible between different observers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9924341      PMCID: PMC1722398          DOI: 10.1136/bjo.82.11.1316

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  19 in total

Review 1.  Ki-67 staining as a means to simplify analysis of tumor cell proliferation.

Authors:  C L Hitchcock
Journal:  Am J Clin Pathol       Date:  1991-10       Impact factor: 2.493

2.  Primary acquired melanosis and melanoma of the conjunctiva: terminology, classification, and biologic behavior.

Authors:  R Folberg; I W McLean
Journal:  Hum Pathol       Date:  1986-07       Impact factor: 3.466

3.  Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy.

Authors:  C M Mooy; P T de Jong; T H Van der Kwast; P G Mulder; M J Jager; D J Ruiter
Journal:  Ophthalmology       Date:  1990-10       Impact factor: 12.079

4.  Conjunctival melanosis and melanoma.

Authors:  R Folberg; I W McLean; L E Zimmerman
Journal:  Ophthalmology       Date:  1984-06       Impact factor: 12.079

5.  Primary acquired melanosis of the conjunctiva.

Authors:  R Folberg; I W McLean; L E Zimmerman
Journal:  Hum Pathol       Date:  1985-02       Impact factor: 3.466

6.  Nucleolar organizer regions (AgNOR) and Ki-67 immunoreactivity in cutaneous melanocytic lesions.

Authors:  F Fogt; A O Vortmeyer; S R Tahan
Journal:  Am J Dermatopathol       Date:  1995-02       Impact factor: 1.533

7.  Ki-67 and bromodeoxyuridine labeling of human choroidal melanoma cells.

Authors:  D S Bardenstein; D H Char; S Kaleta-Michaels; S M Kroll
Journal:  Curr Eye Res       Date:  1991-05       Impact factor: 2.424

8.  Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.

Authors:  P A Hall; D A Levison; A L Woods; C C Yu; D B Kellock; J A Watkins; D M Barnes; C E Gillett; R Camplejohn; R Dover
Journal:  J Pathol       Date:  1990-12       Impact factor: 7.996

9.  Proliferating cell nuclear antigen is required for DNA excision repair.

Authors:  K K Shivji; M K Kenny; R D Wood
Journal:  Cell       Date:  1992-04-17       Impact factor: 41.582

Review 10.  Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva.

Authors:  F A Jakobiec; R Folberg; T Iwamoto
Journal:  Ophthalmology       Date:  1989-02       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.